Methods

Results

Table 1. Patient characteristics at baseline*

Table 2. Disease characteristics at baseline*

Table 3. Molecular characteristics at baseline*

Table 4. Pharmacokinetics of AZD0466 following IV administration

Table 5. AEs observed in >10% of patients*